2028 Marketing Pharmaceuticals Regulations 
Drug Discovery World
JULY 25, 2024
According to data analysts Precedence Research, the global biotechnology market was estimated at $1.38 Following a subdued 2022 and 2023 for biotech investment, there is optimism that the market is heading to recovery in 2024. In 2021, the country had the seventh largest share of the global biotech market 2.
Drug Discovery World
SEPTEMBER 26, 2022
It’s why pharmaceutical companies will often spend up to 10 years and upwards of $1 billion before receiving regulatory approval for a drug. According to MarketWatch, the drug repurposing sector was thought to be worth $25,280 in 2021 and is expected to grow to $30,620 million by 2028 with a CAGR of 2.8%. Benefits and barriers .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Agency IQ
MARCH 7, 2024
British regulators tease new device regulations in informative live session This week, the British regulator MHRA offered a new peek into its planned medical device regulations. BY COREY JASEPH, MS, RAC | MAR 5, 2024 11:10 PM CST Quick background on medical device regulation in the U.K. post-market regulation here.]
The Pharma Data
JANUARY 9, 2021
We are proud to be a leader in the growing public health threat market, enabled by our development and manufacturing expertise, successful public-private partnerships, and broad portfolio of products and CDMO services. “Operationally, we rapidly responded to our customers’ needs, and financially, we delivered record revenue and earnings.
Agency IQ
DECEMBER 15, 2023
The 174 regulations the EPA is currently working on The Environmental Protection Agency has unveiled its Fall 2023 Unified Agenda, which provides a look into the agency’s regulatory agenda for the upcoming year. The expected release dates of the agendas rarely line up exactly with the actual dates when the agency releases the regulation.
Agency IQ
JANUARY 26, 2024
regulators considered the highest-risk IVD devices, and these and devices for self-test by the patient required Notified Body oversight. The IVDR originally gave stakeholders 5 years to comply with the regulation (May 26, 2022). The directive used a list-based system – List A and List B outlined what E.U. Once the E.U.
The Pharma Data
NOVEMBER 4, 2020
Amarin’s decision to continue to invest in expanding the market for VASCEPA also reflects its confidence in its manufacturing processes, which the company has built over a decade to achieve consistent, high-quality, stable supply to support anticipated global demand. commercial team.
Expert insights. Personalized for you.
130 
Let's personalize your content